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Abstract

Background: The human papillomavirus (HPV) is a preventable, sexually transmitted
infection. The vaccines for HPV are safe and effective, but previous research demonstrated that
nursing students have low knowledge levels and vaccine uptake. Low knowledge and attitude
levels in nurses and nurse practitioners can influence parental and patient decision making for
HPV vaccination. Purpose: The purpose of this scholarly project was to evaluate HPV
knowledge and attitudes and their association with vaccination uptake in college nursing
students. There is limited research in the United States on HPV knowledge, attitudes, and uptake
of the vaccine among nursing students. Methods: This project was a replication study utilizing
an anonymous, cross-sectional, online survey methodology to measure the HPV knowledge,
attitudes, and uptake of the vaccine in nursing students. The survey was given to a convenience
sample of undergraduate and graduate nursing students (n = 447) at a private, liberal arts
university. Results: Nursing students had high knowledge and attitude scores. While there were
no significant differences between knowledge between genders (p = .59), there were differences
in knowledge between undergraduate and graduate students (p < .001). There were no
differences in attitude between genders and student classification. Knowledge was not associated
with uptake (p = .63), but there was an association between attitudes and uptake
(p <.001). Conclusion: This study supported that nursing students have high knowledge and
attitude levels towards HPV and HPV vaccination, which may lead to improved vaccination
uptake in the future.

Keywords: HPV infection, papillomavirus vaccines, nurses, vaccinations, health
knowledge, student health, knowledge, attitudes
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Introduction and Background

The human papillomavirus (HPV) is one of the most common sexually transmitted
diseases in the world. HPV affects about 79 million Americans, with the majority in their late
teens or early twenties (Centers for Disease Control and Prevention [CDC], 2017). In the past,
HPV was one of the leading causes of deaths for women in the United States due to cervical
cancer. Incidence rates for cervical cancer have decreased over last 20 years. From 2011 to 2016,
the rate has decreased by 29% for women ages 15 to 24 years old and 13% for women ages 25 to
34 due to increased emphasis on HPV vaccine and routine cervical cancer screening (Guo, Cofie,
& Berenson, 2018).
HPV was found to be the cause of 79% of the 44,000 yearly cases of HPV-related
cancers (Saraiya et al., 2015). Exposure to HPV causes an increased risk for cervical, oral,
penile, vaginal, anal, oropharyngeal cancers and warts. For females, the most common HPVrelated cancer is cervical cancer (48.6%) followed by anal (17.6%), vulvar (16.2%), and
oropharyngeal cancer (14.0%) (CDC, 2019a). Although there has been a significant decline in
cervical cancer rates over the past several decades, rates for HPV-related squamous cell
carcinoma of the oropharynx, anus, and vulva have increased (Van Dyne et al., 2018). The
prevention of HPV tends to focus on females, but males are also at risk for the development of
HPV cancer. For males, the most common HPV-related cancer is oropharyngeal cancer (81.3%)
followed by anal (11.9%) and penile cancer (6.8%) (CDC, 2019a). Although penile cancer is
rare (0.69 per 100,000 men), rates have slightly increased worldwide (Kidd et al., 2017). HPV is
found in half of all penile cancers (American Cancer Society, 2018). These conditions may be
preventable with HPV vaccination. Approximately 51.1% of American adolescents are up to
date on the HPV series, but this is still below the national target goal of 80% for adolescents that
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up to date on HPV vaccination (Healthy People 2020, 2019; Walker et al., 2019). Over half
(68.1%) of American adolescents have had at least one dose of the HPV series, but, about 35%
have completed the series by age 15 (Bednarcyzyk, Ellingson, & Omer, 2019; Walker et al.,
2019).
HPV
HPV is a sexually transmitted disease associated with genital warts and increased risks of
certain cancers (CDC, 2019b). There are more than 200 types of HPV, which are divided into
low-risk and high-risk classifications. Low-risk HPV types are more likely to cause genital, anal,
and oral warts, and high-risk HPV types are more likely to cause cervical, vaginal, vulvar, anal,
penile, and oropharyngeal cancer. Of the 14 high-risk types that can cause cancer, types 16 and
18 cause 70% of pre-cervical lesions and cancers (CDC, 2019b).
HPV-related cancers are easily preventable through immunization and routine cervical
cancer screening. Eighty percent of the population will be infected with HPV at least once during
their lifetime, and in most cases, one’s immune system can overcome the infection without
complications (CDC, 2019c). Cervical cancer is the only type of HPV-related cancer with a
recommendation for routine screening. Since there are no other screenings for other types of
HPV-related cancers and may be undetected for years until symptoms appear, it is even more
important to encourage patients to prevent cancer through immunization.
HPV Vaccines
The CDC recommends the vaccine for males and females age 11 to 12, but the vaccine
may be given as early as nine years old. Females up to age 26 and for males up to age 21 are
eligible to be vaccinated. Although the United States Federal Food and Drug Administration
(FDA) (2018) approved the vaccine for all persons up to age 45 for Gardasil 9, the CDC only
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recommends vaccination for adults age 27 to 45 if they are at a higher risk for infection (Meites
et al., 2019). Adolescents who receive the vaccination between the age of nine to 14 are eligible
to receive the two-dose vaccine six months apart. Those who initiate the vaccine at ages 15 or
older are recommended to receive the three-dose vaccine. Immunocompromised persons nine to
26 years old are also recommended to have the three-dose vaccine.
There are three HPV vaccines approved for use in the United States: Cervarix, Gardasil,
and Gardasil 9. GlaxoSmithKline manufactures Cervarix, and it prevents infections from HPV
16 and 18. Merck & Co. manufacture Gardasil and Gardasil 9. Gardasil prevents infections from
types 6, 11, 16, 18. However, Gardasil 9 is broader in coverage and prevents types 6, 11, 16, and
18 as well as five other types that cause 20% of cancers (types 31, 33, 45, 52, and 58). If the
HPV vaccine for 16 and 18 (Cervarix) covered 100% of the population, then 63.4% (24,548) of
HPV cancer cases (24,548) could be prevented annually and an additional 10% of cases (3,944)
if the 9-valent vaccine were given (Saraiya et al., 2015). These results are agreeable with a
previous meta-analysis from two international HPV vaccine studies (Serrano, 2012). In 2018,
51.1% of adolescents were up-to-date on HPV vaccinations, with 68.1% of the adolescent
population has received at least one dose (Walker et al., 2019). Even though the vaccination rate
has increased, only 35% of adolescents 15 or older have completed the series (Bednarcyzyk et
al., 2019). This is still below the national target goal of 80% (Healthy People 2020, 2019).
One of the key interventions to prevent the spread of HPV and HPV morbidity and
mortality is the uptake of the HPV vaccination. In the United States, there are about 33,700 men
and women who have HPV cancer, but with the vaccine, 32,100 cases could be prevented (CDC,
2019b). Nurses and Advanced Practice Registered Nurses (APRNs) are in a remarkable position
to educate patients, parents, and the community on HPV and vaccination. Patients expect nursing
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professionals to have sound knowledge and understanding if they have questions about the
vaccine. However, there have been few studies focusing solely on the knowledge and attitudes of
HPV and the vaccinations in nursing students (Schmotzer & Reding, 2013).
Among the general undergraduate college student population, there are poor knowledge
and attitudes of HPV and the vaccine. Even more so, there are low rates of HPV vaccine uptake.
As future healthcare workers, nursing students are expected to have higher knowledge levels
regarding HPV, but there is limited research available on nursing students’ knowledge and
attitudes regarding this topic (Schmotzer & Reding, 2013). The lack of information on American
nursing students’ knowledge and attitudes and uptake of the vaccine supports the need for further
research on the topic.
Problem Statement
While there have been many studies on general college students and HPV, there is a gap
in the literature on knowledge and attitudes of HPV and the uptake of the HPV vaccine among
college nursing students.
Purpose
The purpose of this scholarly project was to evaluate HPV knowledge and attitudes, and
their association to vaccination uptake in college nursing students.
Research Questions
In consideration of the project’s purpose to assess HPV knowledge, attitudes, and uptake
in nursing students, the project aimed to focus on the following four questions:
1. What is the knowledge level of undergraduate and graduate nursing students?
2. What are the attitudes of undergraduate and graduate nursing students?
3. What is the vaccine uptake rate among undergraduate and graduate nursing students?
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4. How do knowledge and attitudes affect uptake in undergraduate and graduate nursing
students?
Hypotheses
Based on previous findings in the college population and nursing students, the project
leader hypothesized low knowledge levels in undergraduate and graduate nursing students. Due
to their health care background and training, the project leader also hypothesized there will be a
favorable attitude toward HPV vaccination. The author hypothesized there will be low uptake of
the HPV vaccine among undergraduate and graduate students which is comparable to literature
findings.
Review of Evidence
Previous studies investigated the impact of knowledge and attitudes on the uptake in
college students (Beshers, Murphy, Fix, & Mahoney, 2015; Cunningham-Erves & Talbot, 2015;
Stephens, Tamir, & Thomas, 2016; Barnard, George, Perryman, & Wolff, 2017; Kasymova,
Harrison, & Pascal, 2019). These studies have focused on a single gender, both biological
genders, or minorities. However, to date, there is only one study since 2013 that has explored
knowledge and attitudes in American nursing students and their relationship to HPV vaccination
uptake, but only focused on the differences between ethnicities (Schmotzer & Reding, 2013).
Due to the limited amount of research among American college nursing students regarding this
topic, the discussion will also generalize the knowledge, perceptions, and uptake of the influenza
vaccine to support the review of the literature.
Knowledge
American college students were shown to be aware of HPV but have more deficient
knowledge levels of HPV and HPV vaccination. In studies sampling female students, poor
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knowledge levels were attributed to misinformation or lack of knowledge of HPV and the
vaccine (Licht et al., 2010; Beshers, et al., 2015; Zhang, Tsark, Campo, & Teti, 2015; Stephen,
Tamir, & Thomas, 2016; Kasymova, Harrison, & Pascal, 2019; Kellogg et al., 2019). Females
tended to know more than males about HPV, and females that were vaccinated were more likely
to have higher knowledge levels. Males were revealed to be less aware than women about HPV
and also have weaker knowledge levels (Katz, Krieger, & Robert, 2012; Beshers, et al., 2015;
Cunningham-Erves, & Talbot, 2015; Johnson & Ogletree, 2017). Poor knowledge levels among
men may be influenced by several factors, such as the belief that HPV vaccination is only for
women, the lack of visible symptoms when males are positive for HPV, and the lack of routine
male HPV screening (Kasymova et al., 2019; Fontenot, Fantasia, Charyk, & Sutherland, 2014).
Most college students are aware of HPV, but they lack knowledge about the prevalence of HPV
in the general population and its association with diseases (Kasymova et al., 2019).
Schmotzer and Reding's (2013) study with American nursing students revealed that
students with inaccurate HPV knowledge were more likely to be vaccinated or intended to be
vaccinated. For example, those who were vaccinated were more likely to believe that HPV
caused herpes and did not cause cervical or anal cancer. This group also did not know that the
HPV vaccine was also for men. One study indicated undergraduate nursing students have poorer
vaccine-related knowledge, with 24.7% having high knowledge scores as compared to medical
(74.3%), pharmacy (62.7%), and doctoral nursing students (57.1%) (Dysband, Hall, & Carson,
2019). It is important to educate and train all nursing students to understand the importance of
vaccination. Those with poorer knowledge levels may not have had education or may need
reeducation on HPV and the HPV vaccine. The knowledge they share can impact a patient’s or a
parent’s decision to vaccinate for HPV.
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Attitudes
Positive attitudes towards vaccination were associated with uptake of the vaccine, and
women tended to have more favorable attitudes toward vaccination (Barnard et al., 2017).
Findings in the literature showed females have low levels of perceived HPV severity and risk,
perceived HPV vaccine safety, and perceived social approval (Marchand, Glenn, & Bastani,
2012; Stephens, Tamir, & Thomas, 2016). Generally, males tended to have lower perceived risk
as compared to women. However, if there was an increased risk due to risky sexual behavior or
practices, they were more willing to consider vaccination (Katz et al., 2012; Fontenot et al.,
2014; Johnson & Ogletree, 2017). In several studies, males were less likely to consider
vaccination (Fontenot et al., 2014; Barnard et al., 2017; Kasymova et al., 2019).
Nurses’ attitudes toward vaccination play a significant role in influencing patients. The
bedside or clinic nurse most often meets the patient before the provider. This meeting can set the
tone for the parents’ or the patient’s decision to receive the HPV vaccine. Schmotzer and Reding
(2013) did not address attitudes in their study of nursing students towards HPV. One study
revealed that undergraduate nursing students were more hesitant, less likely to recommend, and
had less confidence in recommending vaccinations in general (Dysband et al., 2019). However,
doctorate nursing students were more confident at discussing vaccines with patients than medical
and pharmacy students. Limiting the concerns and barriers to vaccination among nurses may
result in favorable attitudes towards HPV vaccination and recommendation.
Uptake
Across the literature, 25% to 68.8% of college females and 0% to 52% of college males
were up-to-date on HPV vaccination (Schmotzer & Reding, 2013; Richman, Maddy, Torres, &
Goldberg, 2016; Barnard et al., 2017; Johnson & Ogletree, 2017) Younger students were more
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likely to receive the HPV vaccine, which may be due to the effects of the vaccine being released
in 2006 (Thompson et al., 2017). In nursing students, less than half (28.9%) of the respondents
reported receiving the vaccine (Schmotzer & Reding, 2013). For participants who have not
started the vaccine series or have not completed it, it is recommended to start or complete the
vaccination process for all students to prevent consequences of HPV and transmission of the
virus to others.
Other Influencers to Uptake
Barriers. Other barriers to HPV vaccination are mentioned in the literature. The most
frequent concerns were logistics, cost, insurance, stigma, and fear of side effects (Katz et al.,
2012; Stephens et al., 2016; Martin et al., 2018; Kasymova et al., 2019). Logistics included
waiting time and transportation to a clinic if the vaccine was not offered on campus. Younger
college students may rely on their parents for finances, insurance, and may be embarrassed to ask
them to pay for the vaccination due to perceived sexual stigma (Katz et al., 2012; Martin et al.,
2018). Other historical and current barriers to HPV vaccination uptake are moral and religious
reasons against the vaccine (Vamos, McDermott, & Daley, 2008).
Facilitators. Facilitators to HPV vaccination uptake are recommendations from the
provider, parental influence, increased communication, and perceived risk of HPV (Barnard et
al., 2017; Katz et al., 2012; LaJoie, Kerr, Clover, & Harper, 2018; Marchand et al., 2012;
Stephens, Tamir, & Thomas, 2016). A health care provider’s recommendation is one of the
strongest predictors for the uptake of the vaccine (Gilkey et al., 2016; Kellogg et al., 2019).
Students prefer to receive knowledge from a provider due to their credibility and expertise on
this topic (Lanning, Golman, and Crosslin, 2017). Although parents no longer make medical
decisions for the majority of college students, parental influence may continue to play a role in
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some young adults as college students learn to become independent (LaJoie et al., 2018).
Providing proper education about HPV and the HPV vaccine to parents and students is an
appropriate intervention. Some interventions used to increase communication and awareness of
HPV vaccination are electronic medical record notifications for the providers, provider
education, and social media prompts (Richman et al., 2016; Lanning et al., 2017; Vorsters et al.,
2017; Zhang et al., 2017).
Currently, there is one study since 2013 on the knowledge and attitudes and uptake of the
HPV vaccine in American nursing students (Schmotzer & Reding, 2013). Research indicates
there are poor knowledge levels concerning HPV and the HPV vaccine. More information is
required to assess nursing students' knowledge and attitudes on these topics. Generally, there are
favorable attitudes towards the benefits of vaccination, but undergraduate nursing students were
more hesitant to recommend and inform patients about the purpose, safety, and efficacy of
vaccination (Dysband et al., 2019). Students may not have the knowledge or the confidence to
explain this information to patients and may feel they are imposing on the primary nurse’s
influence on the patient. Also, in Schmotzer and Reding's (2013) study, both male and female
students had a low perceived risk of HPV.
Overall, it appears that undergraduate nursing students scored low in knowledge,
attitudes, and confidence. By addressing misconceptions, removing barriers, and improving the
facilitators, there is an excellent opportunity to increase the knowledge and confidence in
educating patients on this topic. Implications for the nursing students surpass the conclusion of
this project. As future nurses, undergraduate nursing students can influence and inform patients
of HPV and the overall benefits of the vaccine. Graduate nurse practitioner students will become
APRNs who educate, provide anticipatory guidance to parents, and encourage vaccination
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scheduling adherence to parents and patients. Because nurses tend to have more contact with the
patients than any other health care worker, current and correct knowledge, improving
misconceptions, and encouraging our young patients and parents on vaccination is key to
preventing consequences of HPV and transmission to others.
Theoretical Model
The Precautionary Adoption Process Model (PAPM) is a stage theory that describes and
explains the preventative behavior of a health issue (Weinstein, 1988; Weinstein, Sandman, &
Blalock, 2008). Stage theories are useful in describing an individual’s willingness to engage in
preventative behaviors. Because individuals behave differently at each stage, interventions can
be tailored to encourage them to move from one stage to the next. PAPM is similar to the wellknown Transtheoretical Model with its five Stages of Change (pre-contemplation, contemplation,
preparation, action, and maintenance) (Prochaska & DiClemente, 1983). With the Stages of
Change, the model assumes the individual is aware of the health issue, but it does not include
those that are not aware of the issue. The PAPM has a broader scope and recognizes some people
are not aware of specific health problems. Those with no knowledge of HPV have a different set
of obstacles compared to those who are aware of HPV and its consequences.
PAPM differentiates itself from other stage theories through its identification of seven
stages from a person’s awareness to actions for preventative behavior. In Stage One, the
individual is unaware or has not heard of HPV or receiving HPV vaccination for cancer and wart
prevention. A person moves from Stage One to Stage Two after the individual has heard about a
health issue. In Stage Two, the individual is aware of HPV but does not act on the issue. The
person does not consider acting because other issues may compete for personal time and
attention (Weinstein, Sandman, and Blalock, 2008). In Stage Three, the individual is undecided
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about receiving the HPV vaccination. The individual will move out of the action stages into
Stage Four if there is no intention to receive the vaccine. In Stage Five, the individual decides to
get the HPV vaccine. In Stage Six, the individual gets the HPV vaccine. In Stage Seven, the last
stage, the individual engages in the maintenance of the preventative behavior. In this example,
the individual would complete the HPV vaccination series and participate in routine cervical
Papanicolaou (Pap) testing (see Figure 1 for PAPM diagram).
By identifying the stage in which individuals reside, nurses and nurse practitioners can
apply specific interventions for individuals at each of the stages. For example, individuals who
are in Stage One and Stage Two would highly benefit from education on HPV and how to
prevent the consequences of HPV through vaccination and screening. This project does not
address Stage 1, but for participants in Stage 2 with poor knowledge levels, it would be valuable
to educate or reinforce HPV education in this group. Health care providers can target individuals
in Stage Three and Four by looking at barriers and facilitators to HPV vaccination. Those that
are in Stage Five, Six, and Seven will need resources and reminders or assistance in acting in the
maintenance of preventative behaviors.
This scholarly project applies this model through the utilization of an online survey.
Participants who have received zero HPV vaccinations are asked about their willingness to get
the HPV vaccine. This question categorizes participants into the PAPM Stage Two through Stage
Five. By identifying stages in which students most identify with, interventions can be made that
can help them transition into the next stage. The knowledge portion of the survey may indicate
the student classification or age groups that have poorer knowledge levels. Whether or not
students have been vaccinated or not, improving the knowledge of HPV and the vaccines in
those with poor knowledge will be beneficial to their practice and educating their patients.
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Project Design

This scholarly project was a cross-sectional, replication study utilizing an anonymous,
online survey methodology designed to assess the knowledge and attitudes of nursing students
towards HPV and HPV vaccination. Subjects were undergraduate and graduate nursing students
18 or older at Belmont University. Convenience sampling of male and female nursing students
was used for this project. The anonymous survey methodology was low risk to the subjects
allowing it to be verified as exempt by the Belmont University Institutional Review Board.
Clinical Setting
The project took place at Belmont University, a private, Christian, liberal arts university
located in the southeastern United States. The university has 6,820 undergraduate students and
1,621 graduate students with a total of 8,441 students. About 34.6% of the students identify as
male, and 65.4% identify as female. The racial/ethnic diversity is primarily White, non-Hispanic
(79.5%) followed by Hispanic (5.9%); Black, non-Hispanic (5.4%); two or more races, nonHispanic (3.9%); Asian (2.5%); and unknown race/ethnicity or other (2.6%). At the time of this
project, HPV vaccination was not offered through Student Health Services.
Project Population
Inclusion criteria were students 18 years or older at Belmont University. Exclusion
criteria were those less than age 18 or non-nursing majors. There were 800 undergraduate and
graduate nursing students enrolled in the fall semester of 2019 at Belmont University. Power
analyses were conducted using G*Power version 3.1.9.4 statistical software (Faul, Erdfelder,
Buchner, & Lang, 2009). A sample size of 226 was needed for a moderate effect. This was
determined with an alpha of 0.05, power of 0.8, a moderate effect size of 0.5, and an allocation
ratio of 0.2.
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Undergraduate students included traditional nursing students and accelerated nursing
students. Traditional students may have started as freshmen or may be transferred from another
school or program with the opportunity to earn a four-year Bachelor of Science in Nursing
(BSN) degree. The accelerated track was for individuals who have previously obtained a
Bachelor’s degree in another discipline. Of note, the undergraduate nursing program was midway through a curriculum change to a concept-based model to address the vast amount of
content taught in the undergraduate nursing program. Graduate nursing programs offered at
Belmont are Master’s, Post-Master’s to Doctorate, BSN to Doctorate, and post-graduate APRN
with a Family Nurse Practitioner (FNP) concentration. Depending on the student’s progress in
the nursing program, students may or may not have received education on HPV. A survey
question was added to indicate if they have had this content in their curriculum at the time of
participation.
Adolescents and young adults are typically the individuals who receive the HPV vaccine.
Several undergraduate and graduate students will be outside the recommended age range for
vaccination. Older students may have personal reasons for not considering it, such as being in a
married or monogamous relationship for several years. Nevertheless, it is beneficial to know the
knowledge levels and perceptions of all nursing students even though uptake, PAPM staging,
and factors associated with vaccination will be skewed.
Recruitment
Convenience sampling was used to recruit participants for the project. Of the 800 nursing
students, the project leader aimed to recruit approximately 226 participants for the study.
Recruitment strategies include emailed letters, visiting classes, and speaking to students in the
nursing building. A letter of invitation was sent by the Associate Dean of Nursing, on October 1,

HPV VACCINATION

19

2019. The letter invited undergraduate and graduate nursing students to participate in the survey
(see Appendix A for the letter of invitation). The letter of invitation included the purpose of the
survey, the approximate time to take the survey, gift card incentives, and the project leader’s
contact information. Students could access the Qualtrics survey through a link in the email or a
Quick Response (QR) code. The project leader also visited key classes to reach most of the
nursing students. Potential participants received information about the project, estimated time to
take the survey, and ways to access the survey. Printed QR codes were given to the students for
alternate access to the survey (see Appendix B for QR codes). The project advisor also visited
several classes with the project leader to help promote the study. Incentives for the class visits
included candy and the chance to win one of four $25 Amazon gift cards.
Instructions to win one of four $25 Amazon gift cards were placed at the end of the
survey. To be placed in the drawing, participants were instructed to email a screenshot of the
survey submission page to the project leader’s email address. This assures answers could not be
associated with individual participants. Names were placed in an Excel spreadsheet in the order
the email was sent. A random number generator was used for the drawing. The winners were
notified by email with instructions where to pick up the gift card by November 15, 2019.
Sources of Data and Data Collection Instruments
This project replicated a survey by Barnard et al. (2017). The original survey was based
on several previously utilized HPV surveys (Licht et al., 2010; Katz et al., 2012; Marchand et al.,
2012). Permission was granted by the author to alter the survey as needed. The project’s survey
had a total of 53 items: seven demographic questions, 19 knowledge questions, 24 Likert
questions, one question on vaccination uptake, one question on factors related to vaccination, and
one question related to staging. At the beginning of the survey, a short narrative told participants
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about the purpose of the survey, the time it takes to complete, incentives, and implied consent.
Participants can exit the survey at any time if they do not wish to continue (see Appendix C for
HPV survey).
Before collection, the survey was piloted among a group of doctorate nursing students in
their final year of graduate school. Concerns, questions, and suggestions for improvement or
clarity by the cohort were considered for changes to the survey. Barnard et al.’s (2017) survey
was not tested for reliability and validity. Content validity and face validity were verified by a
content expert and the project leader’s advisor.
Demographics. The demographic section included age, gender, student classification
(undergraduate or graduate), ethnicity, whether or not they have received education on HPV, and
whether or not they receive routine, preventative care. The participants’ biological gender was
asked due to the relationship between gender and HPV. This question was placed at the end of
the survey to prevent bias.
Knowledge. Two content experts verified the content validity of the survey. The
knowledge section contained 19 true or false questions regarding HPV and the vaccine. One
question regarding condoms was removed from the original survey. Two additional questions
were added to the knowledge section after discussion with a content expert: 1) “There are many
types of HPV” and 2) “The HPV vaccine covers certain HPV strains.” These questions were
added to assess if students were aware of multiple HPV types and specific HPV vaccines only
protect for particular strains. Two questions were reversed scored. The maximum number of
correct questions that could be acquired was 19. If 14 or more questions were correct, the
participant was considered to have a high level of knowledge regarding HPV. Seven to 13
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questions correct answers indicated a moderate level of knowledge. If six or less questions are
correct, the participant was considered to have a poor level of knowledge.
Attitudes. Susceptibility and concerns (attitudes) were assessed through 24 questions on
a one-to-five Likert Scale (1 – “Strongly Disagree,” 2 – “Disagree,” 3 – “Neutral,” 4 – “Agree,”
and 5 – “Strongly Agree”). The original survey had 25 questions, but one question on the
association of HPV to liver cancer was removed after discussion with the content expert. Three
items were reverse scored. The total score of a participant was calculated by summing the 24
items in this section with a maximum score of 120. A score of one to 41 reflected a poor attitude,
a score a 42 to 89 reflected a moderate attitude, and a score of 90 to 120 reflects a high attitude
level toward HPV and vaccination. Questions within this section were further classified into
perceived susceptibility (10 items), concerns (eight items), vaccine safety (five items), and
vaccine efficacy (one item). Perceived susceptibility had a maximum score of 50 with a score of
one to 19 representing poor levels, 20 to 36 representing moderate levels, and 37 to 50
representing high levels. Perceived susceptibility had a maximum score of 50 with a score of one
to 19 representing poor levels, 20 to 36 representing moderate levels, and 37 to 50 representing
high levels. Concerns had a maximum score of 40 with a score of one to 14 representing poor
levels, 15 to 29 representing moderate levels, and 30 to 40 representing high levels. Vaccine
safety had a maximum score of 25 with a score of one to eight representing poor levels, nine to
17 representing moderate levels, and 18 to 25 representing high levels. Lastly, vaccine efficacy
had a maximum score of 5 with a score of one to two representing poor levels, three representing
moderate levels, and 4 to 5 representing high levels.
Uptake. In the original study, the uptake section asked whether or not participants have
been vaccinated for HPV. If they were not, participants were asked about their thoughts about
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being vaccinated in the fifth section. After discussing with a content expert, participants were
asked how many vaccine doses the participant has received (0, 1, or 2 or more). If participants
chose “zero vaccines,” then they were prompted to the staging question.
Staging and Factors. The fifth section determined the stage participants were in at the
time of they answered the survey. The answers were based on the Precautionary Adoption
Process Model (Weinstein, 1988; Weinstein, Sandman, & Blalock, 2008). The last section
assessed influences toward vaccination (provider, family, friends, and the belief the virus or the
vaccine can cause health problems) through a multiple select question.
Data Collection Process/Procedures
Data collection began on October 1, 2019 and was scheduled to end on October 31, 2019.
On October 1, 2019, the HPV survey was sent to the students via email by the associate dean of
nursing. This letter included the purpose of the survey, the approximate time to take the survey,
gift card incentives, and contact information. Students were able to access the Qualtrics survey
through a link in the email or a QR code.
To optimize response rate, professors of undergraduate and graduate nursing classes were
contacted in the Spring and Fall semester of 2019 for permission to speak to their students about
the scholarly project. Professors that agreed to the visit allowed the project leader to speak to
their class for five to ten minutes. The project leader visited the following classes during
October: Wellness, Assessment, and Health; Perspectives; Care Management I; Care
Management II; Transition to Graduate Nursing; Pediatrics; Nursing Leadership; Childbearing;
and Advanced Health Assessment. These classes were chosen to reach as many nursing students
who were in the older undergraduate curriculum, newer concept-based curriculum, and graduate
nursing students. Potential participants received information about the project, estimated time to

HPV VACCINATION

23

take the survey, and ways to access the survey. Printed QR codes were given to the students.
Incentives for the class visits included candy and the chance to win one of four $25 Amazon gift
cards. The project advisor also visited several classes with the project leader to help promote the
study. If time allowed, the students were able to take the survey during class time. In between
classes, the project leader recruited students in the lobby and hallways of the nursing building.
Because the response rate was greater than 50%, the survey ended early on October 23, 2019,
with approval from the project leader advisor.
Data Analysis. Data was downloaded into an Excel spreadsheet and transferred to SPSS
Statistics 19.0. An alpha level of 0.05 was used to determine statistical significance. Independent
variables were demographic information, knowledge, attitudes, stage in PAPM, and factors
associate with uptake. The dependent variable was the uptake of the HPV vaccine.
Descriptive statistics, chi-square, and independent t-tests compared data between genders
and student classification (undergraduate or graduate). Knowledge is a dichotomous variable,
and the independent t-test was used to find the difference in knowledge scores between genders,
student classification, and vaccine uptake. Although the uptake of the vaccine had three possible
options, it was treated as a dichotomous variable to find a relationship in the independent
variables. Since attitude was measured with a Likert-scale, it is a scale variable. Logistic
regression was used to correlate knowledge between genders, student classification, and vaccine
uptake. PAPM staging and factors associated with uptake are nominal variables, and Chi-square
was used to measure their association with gender, student classification, and uptake.
Results
The total number of participants was 507 with a response rate of over 60% of all nursing
students attending the fall semester of 2019. Several participants were omitted from the final
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analysis for 1) identifying as being below the age of 18 (n = 1), 2) not answering more than half
of the knowledge and attitude sections (n = 59), and 3) identifying as “Other” for the gender (n =
1). The final number of surveys included in the data analysis was 447. One student did not
answer a majority of the attitude questions and was removed for the attitude analysis (n = 446).
Unanswered questions appeared to be missing at random, and data was not imputed for the
knowledge section. If participants missed a question, it was assumed they did not know the
answer and was considered incorrect. Data were imputed for the attitudes section with the mean
score for each question.
Demographics
Demographic information included age, gender, student classification, ethnicity,
engaging in preventative health care, HPV education, and HPV vaccination uptake. The age of
the participants ranged from 18 to 62 years with a mean of 22.5 years (SD = 4.69). The majority
of the participants reported being female (93.1%, n = 416), White (87.3%, n = 391), and
undergraduate student students (84.1%, n = 376). Most of the respondents participated in
routine, preventative health care (89%, n = 398). Of the 447 responses, 31.1% (n = 139) had
zero HPV vaccinations and 68.9% (n = 308) having at one or more doses (see Table 1 for
demographics).
Knowledge Results
The maximum knowledge score in this survey was 19. Knowledge scores for the
participants ranged from three to 19 with a mean knowledge score of 14.6 (SD = 2.39). The
majority of the participants (61.7%, n = 311) had a high knowledge level of HPV followed by
moderate levels (30%, n = 134) and low levels (0.4%, n = 2) (see Table 2 for knowledge scores
for all participants). The top three questions students answered incorrectly were 1) “HPV is
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transmitted by skin-to-skin contact,” 2) “Most adults are infected with HPV,” and 3) “There is a
routine HPV test for men.” These questions were related to transmission, prevalence, and
screening guidelines.
The independent t-test showed there were no significant differences between the
knowledges score for males (M = 14.84, SD = 2.62) and females (M = 14.60, SD =2.37), t(445)=
.544, p = .59, d = 0.96 (see Table 3 for t-Test for Independent Groups – Knowledge). Graduate
students (M = 15.6, SD = 2.46) had a higher mean knowledge score than undergraduate students
(M = 14.4, SD = 2.34), t(444) = -3.92, d = -.5, p < .001. Furthermore, there were some
statistically significant differences on certain items between undergraduate and graduate
students. More undergraduate students incorrectly answered items related to transmission, cure,
and cancer caused by HPV compared to graduate students. Nearly 47.1 % (n = 177) of
undergraduate students knew that HPV is transmitted by skin-to-skin contact, 2 (1, N = 446) =
4.87,  = .1, p = .027. Undergraduates (68.6%, n = 258) were also more likely to believe that
there is no cure for HPV, 2 (1, N = 446) = 4.67,  = .1, p = .031. Finally, a smaller percentage
of undergraduate students were aware that HPV could cause oral cancer (58.2%, n = 219) and
anal cancer (68.4%, n = 257) than graduate students (see Table 4 for Knowledge – Correct
Answers).
The mean knowledge score was similar between those who were unvaccinated (M =
14.53, SD = 2.58) and those who had received at least one vaccination (M = 14.65, SD = 2.31),
t(445) = -4.78, d =. -.049, p = 0.63. Additionally, there were no differences in having HPV
education (M=14.3, SD = 2.33) or not having HPV education (M = 14.7, SD = 2.41), t(444) = 1.29, d = -.17, p = .2 (see Table 3 for t-Test for Independent Groups – Knowledge).
Attitude Results
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The mean attitude score for all participants was 91.2 (SD = 9.99) and ranged from 36 to
110. A low numeric attitude score represented a more negative attitude towards HPV and HPV
vaccination. A higher numeric attitude score represented a more positive attitude. The majority
of participants had a high attitude score (61.7%, n = 276) followed by moderate levels (37.8%, n
= 169) and low levels (0.4%%, n = 2). Most respondents had a high level of perceived
susceptibility (97.1%, n = 434) and a moderate level of personal and social concerns towards
HPV and vaccination (91.9%, n = 411). The majority of participants had high levels of
confidence in vaccine safety (67.2%, n = 300) and vaccine efficacy (82.6%, n = 369) (see Table
5 for attitude scores for all participants).
Unvaccinated participants (M = 87.3, SD = 12.1) had a lower mean attitude score (M =
93, SD = 8.28), t(445) = -5.02, d = -.055, p < .001. There were no differences between the
overall attitude scores of males (M = 89.2, SD = 8.2) and females (M = 91.4, SD = 10.1), t(445) =
-1.18, D = -.024. p = .24 and in undergraduate (M = 91.3, SD =9.85) and graduate students (M =
90.8, SD = 10.54), t(444) = .42, d = -.049, p = .67. Attitude levels were not associated with
having HPV education (M = 91.5, SD = 9.76) or not having HPV education (M = 89.6, SD =
10.72), t(445) = -1.61, d = .19, p = .11 (see Table 6 for t-Test for Independent Groups –
Attitudes).
Chi-square analysis revealed differences on several items in those who “somewhat
agreed” or “strongly agreed” on an item and participants who did not. Male students (n = 18,
58.1%) were less likely to agree that HPV would be a severe threat to their health than females
(n = 313, 75.2%), 2 (1, N = 446) = 4.43,  = .1, p = .04. There were no significant differences
between undergraduate and graduate students on any item (see Table 7 for Attitudes – Percent
“Strongly Agree” and “Somewhat Agree”).
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Uptake
Participants age 18 to 20 (37.3%, n = 115) and age 21 to 29 (58.8%, n = 181) reported
higher rates of vaccination compared to participants age 30 or older (3.9%, n = 12) (see Table 1).
There were several statistically significant results with the chi-square analysis for uptake.
Between genders, more females (71.2%, n = 295) had at least one HPV vaccination compared to
males (38.7%, n = 12), 2 (1, N = 447) = 14.17,  = .18, p <.001. Those who had HPV education
(85.4%, n = 263) were more likely to be vaccinated than those who did not have HPV education
(14.6%, n = 45), 2 (1, N = 447) = 18.8,  = .21, p <.001. Likewise, students who participate in
regular, preventative healthcare (71.6%, n = 285) were more likely to be vaccinated that those
who did not (46.9%, n = 23), 2 (1, N = 447) = 12.4,  = .17, p <.001. There were no differences
in uptake between undergraduate (69.9%, n = 263) and graduate students (64.3%, n = 45), 2 (1,
N = 446) = .86,  = -.045, p = .38. Vaccination (78.4%, n = 109) was associated with the belief
vaccines do not cause problems, 2 (1, N = 447) = 44.4,  = -.32, p <.001. The majority of
unvaccinated participants 49.6% (n = 69) reported not being offered the vaccine, 2 (1, N = 447)
= 152.3,  = -.58, p <.001 (see Table 8 for Chi-square Analysis for Independent Groups –
Uptake).
PAPM
The majority of males (78.9%, n = 15), females (57.5%, n = 69), undergraduate (61.9%,
n = 70) and graduate students (52%, n = 13) who were not vaccinated reported never thinking
about getting the HPV vaccination. One male (5.3%) and 16 females (13.3%) intended to get the
vaccine within six months. Sixteen undergraduate students (13.3%) and two (8%) of graduate
students intend to be vaccinated within six months. Twenty-three females (19.2%) and two
graduate students (32%) decided against vaccination (see Table 9 for PAPM staging). Chi-square
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analysis showed no significant association between those who did not participate in preventative
health care and never thinking about the getting the vaccine, 2 (1, N = 139) = 2.14,  = .12, p =
.21 (see Table 10 for Chi-square Analysis for Preventative Care and Never Getting the Vaccine).
Factors Associated with Vaccination
Logistic regression was completed to indicate factors associated with vaccination status.
The Hosmer and Lemeshow Test confirmed a good fit, 2 (6, N = 447) = 8.36, p = .21). This
model predicted 70.5% of the vaccination statuses in this study. Significant factors for
vaccination were provider offered (p = <.001), family (p = <.001), belief the vaccine does not
cause problems (p = <.001), belief the virus causes problems (p = .047), and no one offered the
vaccine (p = <.001). More females (68.3%, n = 284) reported that providers recommended the
vaccine to them than males (29%, n = 9), 2 (1, N = 447) = 17.69,  = .21, p = <.001. Of the
vaccinated participants, 97.2% (n=172) reported family influence as a factor to being vaccinated.
Participants were 39.6 times more likely to get the vaccine if their family encouraged them and
10.6 times more likely if a provider offered it to them. A friend’s recommendation was not
statistically significant as a factor to vaccination (see Table 11 for Factors Associated with
Vaccination).
Discussion
The purpose of this scholarly project was to evaluate HPV knowledge and attitudes, and
their association to vaccination uptake in college nursing students. This project expanded on a
previous study by Bernard et al. (2017), which examined the effect knowledge and attitudes have
on HPV vaccination uptake and added a focus of a specific population of college nursing
students. The last study on the topic of HPV and nursing students was in 2013 and occurred in
New Mexico (Schmotzer & Reding, 2013). This project and Barnard et al.’s (2017) study were
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located in the South and used the PAPM model for its theoretical basis. All three studies differed
in ethnicity, student classification, and the students’ disciplines of study.
Nursing programs usually have a smaller percentage of males to females. Gender
percentages among nursing students mirrored those in Schmotzer and Reding’s (2013)
population of nursing students but differed from Barnard et al.’s (2017) population since they
surveyed the entire campus. Ethnicity among this sample population was similar to the setting of
the project and Barnard et al.’s (2017) population. Schmotzer and Reding’s(2013) study had an
almost equal number of Hispanics and non-Hispanics attending the nursing school near the U.S.Mexico border
The majority of the nursing students had high knowledge levels (61.7%, n = 311), with
only 0.4% having low knowledge levels. This finding differed from the project's hypothesis of
the presence of low knowledge levels among nursing students and may be attributed to the
medical and healthcare interests of the sample. Additionally, there has been a drive to increase
HPV vaccination and education from primary care providers and media over the last several
years. The majority of students (79.9%, n = 357) reported having HPV education before taking
the survey. Undergraduate students generally begin receiving HPV education in their third or
fourth year but may have received some HPV information earlier with the change in nursing
curriculum at the university. Schmotzer and Reding’s (2013) study did not report the knowledge
levels in their research, but the majority of the participants answered eight of the 19 (42.1%)
knowledge questions incorrectly in the study. A survey of the general student body revealed
moderate knowledge levels at the undergraduate level (Barnard et al., 2017). Similar to Barnard
et al.’s, (2017) study, most participants incorrectly answered questions on HPV transmission,
prevalence, and screening guidelines. Undergraduate nursing students were more likely to miss
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questions regarding transmission, cure, and cancer caused by HPV. The lack of knowledge in
these areas may require nursing education to increase or reinforce this information. These facts
are important in educating patients and preventing the spread of HPV.
Males and females had similar knowledge scores, which mirrored the parent study
(Barnard et al., 2013). Schmotzer and Reding’s (2013) study did not look at the difference
between males and females. Graduate students (M = 15.6, SD = 2.46) had a higher mean score
than undergraduate students (M = 14.4, SD = 2.34), t(444) = -3.92, d= -.5, p < .001. This finding
was not unexpected since they were in an advanced nursing program to become NPs.
Undergraduate students may have had some HPV education, but not to the extent of advanced
nursing students. Knowledge was not affected by vaccination status or having previous HPV
education.
Nursing students possessed high attitude levels (61.7%, n = 276). Further analysis
revealed the majority of students had high levels of perceived susceptibility (97.1%, n = 434),
moderate personal and social concerns (91.9%, n = 411), and high levels of confidence in
vaccine safety (91.9%, n = 411) and efficacy (82.6%, n = 369). Due to their background and
training in healthcare, it is expected for this population to have higher attitude levels compared
with the general student population. The general student population had lower (moderate) levels
of perceived risk as compared to this project’s evaluation of perceived susceptibility (Barnard et
al., 2017). The previous nursing study did not examine attitudes and beliefs.
Nurses play a key role in the safety and optimization of the health of families and patients.
For all nurses, the primary approach is to educate. This approach may begin with listening for
any concerns and addressing those specific concerns with sound research regarding the risks and
benefits of vaccination. Knowledge of HPV, consequences, prevention, vaccination
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contraindications, and side effects will be helpful in alleviating the fears and concerns of parents
and patients. This may happen formally in the clinic or informally in social settings or social
media. NPs regularly counsel and order vaccinations for patients. NPs may begin the process of
HPV vaccination through anticipatory guidance before the child reaches the age of nine allowing
parents time to make a thoughtful, educated decision before the next well-child appointment.
Although several factors influence the decision to vaccinate, attitude was associated with
vaccination status (M = 93, SD = 8.28), t(445) = -5.02, d = -.055, p < .001. There was no
statistical difference between attitude and gender (p = .24), student classification (p = .67), or
HPV education (p = .11). Gender differences in 12 questions were found in the previous study of
the general student population, but only in one question for this project (Barnard et al., 2013). In
both studies, men were less likely to agree that HPV would be “a severe threat to their health” as
compared to females, similar to the previous study. A high percentage (96.3%, n = 426)
understood that HPV could be transmitted without having signs or symptoms; however, men did
not see themselves at risk. Presenting HPV vaccination as a form of herd immunity may be an
effective method to increase uptake. Vaccination decreases health risks for the vaccine recipient
but also protects future sexual partners. A nurse’s attitude toward vaccination can influence
personal uptake of the vaccination but also a parent’s decision. If a nurse has a negative attitude
towards vaccination, it can dissuade a parent from vaccinating, especially one who trusts the
nurse’s medical opinion.
The majority of the students (68.9%, n = 308) reported receiving at least one dose. This
percentage is higher than previous studies ranging uptake from zero to 68% (Schmotzer &
Reding, 2013; Richman, Maddy, Torres, & Goldberg, 2016; Barnard et al., 2017; Johnson &
Ogletree, 2017). These statistics also include Schmotzer and Reding’s (2013) study in which
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28.9% of nursing students reported being vaccinated against HPV. Similar to Barnard et al.’s
(2013) study, more females (47.3%) reported having at least one vaccine dose. Participants
(73.7% , n = 263) who had routine, preventative health care and previous HPV education
reported to have at least one dose of the vaccination. This finding suggests that those who
participate in preventative health care, whether it be having a primary care provider or going to
the school clinic for routine checks or immunizations, are more likely to be vaccinated. As a
healthy, young student, most of the general students may not see the need for primary care.
Educating the importance of an annual check, preventative measures, and routine vaccination can
decrease the disease and illness.
A small percentage of vaccinated participants (14.6%, n = 45) indicated they did not have
HPV education. These participants may have received the vaccination as part of their childhood
immunizations and may or may not understand the purpose of the vaccine. Educating parents on
HPV and the role of the vaccine can assist them in making informed vaccine decisions for their
children. Older students were more likely to be unvaccinated, which may be attributed to vaccine
being released in 2006 and the recent advancement in educating and awareness of HPV over the
last several years. There were no differences in uptake between undergraduate and graduate
students (p = .35).
The PAPM model was used to describe the stage of change unvaccinated participants
were occupied. The majority of unvaccinated males, females, undergraduate and graduate
students reported being in Stage 1 (unawareness) and Stage 2 (unengaged) (60.4%, n = 84) or
Stage 4 (decided against) (17.3%, n = 24). These higher rates of Stage 1 and 2 highlight the need
to increasing awareness and education of HPV and risks and benefits of HPV vaccination among
students. This study possibly prompted participants in this group to begin thinking about

HPV VACCINATION

33

vaccination. Several students (12.2%, n = 17) intend to be vaccinated within the next six months.
These students would benefit with information about HPV, vaccination, and accessing a
provider. Although 24 students did decide against vaccination, emphasis on safe, sexual practices
and routine pap screens are alternate recommendations nurses can educate these patients on
limiting the spread of HPV. Despite the association between having preventative healthcare and
uptake, there was no association between lack of preventative healthcare and “never thinking of
vaccination” (p = .21).
Stage 7 (maintenance) was not addressed in the survey. Aside from vaccination, other
preventative measures for HPV are safe, sexual practices (condom and dental dam use). It is
important to educate patients on the abstinence if genital warts are present, because the virus is
more likely to be transmitted during this time. Although there is not a cure for genital warts,
there are treatment options such as topicals and surgery. For females, routine pap tests are
essential for early screening of HPV. Despite no recommendations for screening for HPV in
males, men who have sex with men who are considered high-risk may consider periodic anal pap
tests (CDC, 2015)
Consistent with the literature, provider recommendation was a significant factor for
vaccination (Gilkey et al., 2016; Barnard et al., 2017; Kellogg et al., 2019). In this sample, the
family influence was markedly significant. Participants were 39.6 times more likely to be
vaccinated if the family recommended vaccination as compared to Barnard et al.’s (2017) finding
of a 1.89 increased likelihood. Similar to Barnard et al.’s (2017) finding, participants in this
sample were 10.6 times more likely to be vaccinated if a provider recommended the vaccine.
When children are young, the medical decision making generally belongs to the parents. In the
previous study, both provider and family/friends influence were factors to vaccination (Barnard
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et al., 2017). Family and parental beliefs concerning vaccination certainly play a significant role
in the health of a young child. Young adults may not recall a provider's recommendation or
education on HPV from when they are young. Parents make the ultimate decision for young
children and adolescents' vaccinations. It is part of the nurse's role to educate the parents and
patients. Discussing the vaccine as a cancer prevention method may highlight the importance of
the vaccine to both parties.
Practice Implications
Nurses play a key role in safety and optimizing the health of families and patients. For all
nurses, the primary approach is to educate. This may begin with listening for any concerns and
addressing specific worries with research and the risks and benefits of vaccination. Knowledge
of HPV, consequences, prevention, vaccination contraindications and side effects will help
alleviate the fears and concerns of parents. This may happen formally in the clinic or informally
in social settings or social media. With the NPs’ scope of practice, they may regularly care for
patients and order the HPV vaccine. NPs may begin the process of HPV vaccination through
anticipatory guidance with families when a child is eight or nine years old. This allows parents
time to make a thoughtful, educated decision before their next well-child appointment.
It is also important for nurses to not only be knowledgeable but also have a favorable
attitude towards vaccination. Confidence in the safety and efficacy of the vaccine can affect
parental decisions in vaccination. A positive attitude can make vaccination seem more favorable
to parents and patients, especially in those who trust and value the medical opinion of the RNs
and NPs at the clinic.
The results of the study may assist nursing educators in the effectiveness of their HPV
education in their program. The students of this program did have high knowledge levels, but
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educators can emphasize transmission, prevalence, and screening guidelines. Knowledge and
attitudes towards HPV and vaccination also have implications from a public health perspective.
The benefits of the vaccine are health optimization, cost, reduction of possible emotional
distress, and mitigation of viral transmission, warts, and cancer. Fourteen million people are
infected yearly with HPV, and usually, HPV resolves without treatment (CDC, 2017). When it
does not resolve, it can cause warts and cancer. Uptake of the vaccine can prevent the spread of
disease and decrease the risk of warts and cancer in an especially vulnerable community.
Strengths and Limitations
A strength of this project included a high response rate and sample size. Over 60% (n
= 507) of nursing students started the survey. This project had 447 surveys included in the
analysis compared to the parent study (n = 383). As a replication study, this project was able to
support the previous study. This study also included both undergraduate and graduate nursing
students, instead of solely undergraduate students. To the project leader's knowledge, this was
the second study to use the PAPM to assess college students' knowledge, attitudes, and uptake of
the HPV vaccine. This project was the only study to address the knowledge gap concerning HPV
and American nursing students since 2013. As future nurses and providers, providing accurate
information and evidence about HPV gives patients, parents, and the community the means to
make an informed decision about being vaccinated.
Limitations of this study were the use of cross-sectional design and a self-reported survey.
The self-reported survey was not proctored; therefore, participants had the opportunity to search
for the information on HPV while taking the survey, possibly skewing the data on knowledge.
This was a convenience sample at a private, religious, liberal arts university of nursing students
in the Southeastern U.S. Generalizability was limited because nursing students are assumed to
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have more healthcare knowledge compared to the general college students. It also lacked
generalizability to nursing students because the sample came from a private, religious university.
This is not reflective of many schools of nursing in the United States. Although adapted from a
previous study, this instrument was not tested for reliability and validity. Data may have been
skewed with some participants being older or in a long-term, monogamous relationship and
viewed this topic as inapplicable. Social desirability response bias may have been present as the
target population was nursing students and answered questions in a manner congruent with
health care's pro-stance on vaccination. Finally, this project did not ask questions on completion
of all doses of the HPV vaccine. Some participants may have started the process and have
forgotten or decided to stop the vaccinations. Although the data will show if they have received
the vaccine, it does not indicate if they are up to date on HPV vaccinations. This project did not
follow-up on student’s vaccination status or participation in preventative screening.
Conclusion
This replication deepened the insight into the knowledge, beliefs, and uptake of the HPV
and HPV vaccination in undergraduate and graduate nursing students. This study also
contributed to closing the gap in research concerning nursing students and HPV. This study
supported that nursing students, who will be at the forefront of providing health care, have high
levels of knowledge and positive attitudes toward HPV and HPV vaccination. Without
minimizing concerns and worries for vaccination, nurses can educate parents on how the benefits
outweigh the risks for vaccination. The use of the Precaution Adoption Process Model helped
identify the stage of change the unvaccinated students resided. Developing appropriate
interventions for each stage aids in uptake. Finally, from a public health perspective, increasing
the uptake of vaccination decreases transmission and risk of warts and cancer in a community.
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Figure 1: Precautionary Adoption Process Model (adapted from Weinstein, Sandman, and
Blalock, 2008).
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Table 1: Demographics
Age
Mean Age
Range
18-20
21-29
>30
Gender
Male
Female
College Classification
Undergraduate
Graduate
Ethnicity
Caucasian
African-American
Hispanic
Middle Eastern
Asian
Other
Preventative Healthcare
No
Yes
Vaccination Uptake
No Vaccinations
1 Dose
2 or More doses
> 1 Vaccination Dose
Age 18-20
Age 21- 29
> Age 30
HPV Education
No
Yes

22.5 (SD=4.69)
18 – 62
37.1% (n = 166)
55.9% (n = 250)
6.9% (n = 31)
6.9% (31)
93.1% (416)
84.1% (n = 376)
15.7% (n = 70)
87.3% (n = 391)
2% (n = 9)
3.4% (n = 15)
1.6% (n = 7)
3.4% (n = 15)
2.2% (n = 10)
11% (n = 49)
89% (n = 398)
31.1% (n = 139)
17.2% (n = 77)
51.7% (n = 231)
37.3% (n = 115)
58.8% (n = 181)
3.9% (n = 12
20.1% (n = 90)
79.9% (n = 357)
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Table 2: Knowledge Scores for All Participants
Knowledge
Mean Knowledge Score
Range
Low
Moderate
High

14.61 (SD =2.39)
3 - 19
.4% (n = 2)
30% (n = 134)
69.6% (n = 311)
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Table 3: t-Test for Independent Groups – Knowledge
Gender
Male

Female

df

t

d

p

14.84 (2.62)

14.6 (2.37)

445

.544

.096

.59

Student
Classification
Knowledge
Mean (SD)

Undergraduate

Graduate

df

t

d

p

14.4 (2.34)

15.6 (2.46)

444

-3.92

-.50

<.001

Uptake
None

>1

df

t

d

p

14.53 (2.56)

14.65 (2.31)

445

-4.78

-.049

.63

HPV Education
Yes

No

df

t

d

p

14.3 (2.33)

14.7 (2.41)

444

-1.29

-.17

.2
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Table 4: Knowledge – Correct Answers
Questions

All

Gender
Male

1. Genital warts
are caused by
HPV
2. HPV can
cause cervical
cancer
3. Abnormal pap
tests may
indicate that a
woman has
HPV
4. HPV can
cause penile
cancer
5. HPV is
transmitted by
skin-to-skin
contact
6. HPV infects
both men and
women
equally
7. HPV is
sexually
transmitted

Student
Female



Classification

p

Undergrad

Graduate



p

72%
(n = 322)

80.6%
(n = 25)

71.4%
-.052
(n = 297)

.37*

70.7% (n =
266)

78.6%
(n = 55)

.063

.18

95.3%
(n = 426)

90.3%
(n = 28)

95.7%
(n = 398)

.064

.17**

94.4% (n =
355)

100%(n = 70)

.096

.058**

87.9%
(n = 393)

96.8%
(n = 30)

87.3%
-.077
(n = 363)

.16**

87.8% (n =
330)

88.6%
(n = 62)

.009

1**

60.2%
(n = 269)

58.1%
(n = 18)

60.3%
(n = 251)

.012

.80

58.5% (n =
220)

68.6%
(n = 48)

.075

.12

49.2%
(n = 220)

54.8%
(n = 17)

48.8%
-.031
(n = 203)

.52

47.1% (n =
177)

61.4%
(n = 43)

.1

.027

61.1%
(n = 273)

58.1%
(n = 18)

61.3% (
n = 255)

.017

.72

61.2% (n =
230)

60%
(n = 42)

-.009

.85

96.6%
(n = 432)

96.8%
(n = 30)

96.6%
-.002
(n = 402)

1**

96.3% (n =
362)

98.6%
(n = 69)

.046

.48**
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8. I can transmit
HPV even if I
don't have
symptoms
9. Most persons
with HPV
have no
visible signs
or symptoms
10. HPV can lay
dormant in the
body for years
without
symptoms
11. There is a
vaccine
available to
prevent HPV
infection

95.3%
(n = 426)

96.8%
(n = 30)

95.2%
-.019
(n = 396)

1**

94.9%
(n = 357)

97.1%
(n = 68)

.038

.55**

91.1%
(n = 407)

93.5%
(n = 29)

90.9%
-.024
(n = 378)

1**

90.7%
(n = 341)

92.9%
(n = 65)

.028

.72*

96%
(n = 429)

96.8%
(n = 30)

95.9%
-.011
(n = 399)

1**

95.5%
(n = 359)

98.6% (
n = 69)

.057

.33**

94.6%
(n = 423)

100%
(n = 31)

100%
(n = 394)

.013

.68

94.1%
(n = 354)

98.6%
(n = 69)

.073

.15**

12. There is no
cure for HPV
13. Most adults
are infected
with HPV
14. HPV infection
among men is
rare
15. HPV can
cause oral and
throat cancer

70.5%
(n = 315)
38%
(n = 170)

74.2%
(n = 23)
38.7%
(n = 12)

70.2%
-.022
(n = 292)
38%
-.004
(n = 158)

.79*

68.6%
(n = 258)
37.2%
(n = 140)

81.4%
(n = 57)
42.9%
(n = 30)

.1

.031

.042

.37

80.1%
(n = 358)

74.2%
(n = 23)

80.5%
(n = 335)

.040

.54*

79.8%
(n = 300)

81.4%
(n = 57)

.015

.75

61.5%
(n = 275)

67.7%
(n = 21)

61.1%
-.035
(n = 254)

.46

58.2%
(n = 219)

78.6%
(n = 55)

.152

.001

.94
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16. HPV can
70.2%
cause anal
(n = 314)
cancer
17. There is a
55.7%
routine HPV
(n = 249)
test for men
18. There are
91.1%
many types of
(n = 407)
HPV
19. The HPV
94.9%
vaccine covers (n = 424)
certain HPV
strains
* Yates continuity correction
**Fisher’s Exact Test
 = effect size

50
64.5%
(n = 20)

70.7%
(n =294)

.034

.47

68.4%
(n = 257)

80%
(n = 56)

.093

.05

61.3%
(n = 19)

55.3%
-.031
(n = 230)

.52

54.3%
(n = 204)

64.3%
(n = 45)

.073

.12

93.5%
(n = 29)

90.9%
-.024
(n = 378)

1**

91%
(n = 342)

91.4%
(n = 64)

.006

1*

93.5%
(n = 29)

95%
(n = 395)

.67**

93.9%
(n = 353)

100%
(n = 70)

.10

.035**

.016
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Table 5: Attitude Scores for All Participants
Attitudes
Mean Score
Range
Low
Moderate
High
Perceived Susceptibility
Mean Score
Range
Low
Moderate
High
Concerns
Mean Score
Range
Low
Moderate
High
Vaccine Safety
Mean Score
Range
Low
Moderate
High
Vaccine Efficacy
Mean
Range
Low
Moderate
High

91.2 (SD = 9.99)
36 - 110
0.4% (n = 2)
37.8% (n = 169)
61.7% (n = 276)
41.63 (SD = 5.58)
18 - 50
0.2% (n = 1)
2.7% (n = 12)
97.1% (n = 434)
22.1 (SD = 4.16)
7 - 33
4.3% (n = 19)
91.9% (n = 411)
3.8% (n = 17)
19.2 (SD = 3.86)
5 - 25
0.9% (n = 4)
32% (n = 143)
67.2% (n = 300)
4.2 (SD = 1)
1–5
6.9% (n = 31)
10.5% (n = 47)
82.6% (n = 369)
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Table 6: t-Test for Independent Groups – Attitudes
Gender
Male

Female

df

t

d

p

89.2 (8.2)

91.4 (10.1)

445

-1.18

-.024

.24

Student
Classification
Attitudes
Mean (SD)

Undergraduate

Graduate

df

t

d

p

91.3 (9.85)

90.8 (10.54)

444

.42

-.049

.67

Uptake
None

>1

df

t

d

p

87.3 (12.1)

93 (8.28)

198.3

-5.02

-.055

<.001

HPV Education
Yes

No

df

t

d

p

91.5 (9.76)

89.6 (10.72)

445

-1.61

.19

.11
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Table 7: Attitudes - Percent “Strongly Agree” and “Somewhat Agree”
Questions
All
Gender
(N=447)

1. I am at risk for
getting HPV
2. I am likely to
contract the
HPV virus in
my lifetime
3. HPV would be
a severe threat
to my health
4. HPV would be
a serious
threat to my
sex life
5. HPV would
make it
difficult to
find a longterm partner
6. I would tell
my sexual
partner if I
had HPV
7. If I had HPV I
would be at
risk for
transmitting it
to others

Student Classificati
on (N =.
446)

17.4%
(n = 78)
26.6%
(n = 119)

Male
12.9%
(n = 4)
22.6%
(n = 7)

Female
17.8%
(n = 74)
26.9%
(n = 112)


.03

p
.63**

Undergrad
18.1%
(n = 68)
27.1%
(n = 102)

Graduate
14.3%
(n = 10)
24.3% (n =
17)


-.036

p
.44

.03

.75*

-.023

.62

74%
(n = 331)

58.1%
(n = 18)

75.2%
(n = 313)

.1

.04

75.5%
(n = 285)

65.7%
(n = 46)

-.084

.077

72.3%
(n = 323)

64.5%
(n = 20)

72.8%
(n = 303)

.05

.32

72.6%
(n = 273)

70%
(n = 49)

-.021

.65

58.8%
(n = 263)

54.8%
(n = 17)

59.1%
(n = 246)

.02

.64

60.4%
(n = 227)

51.4%
(n = 36)

-.066

.16

93.3%
(n = 417)

93.5 %
(n = 29)

93.3%
(n = 388)

-.003

1**

93.9%
(n = 353)

91.4%
(n = 64)

-.036

.62*

87.7%
(n = 392)

83.9%
(n = 26)

88%
(n = 363)

.032

.7*

87.5%
(n = 329)

90%
(n = 63)

.028

.7*
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8. I would need
the HPV
vaccine if I
had a high
number of
sexual
partners
9. I would need
the HPV
vaccine if I
had multiple
sexual
partners
10. I would need
the HPV
vaccine if I
had a family
history of
cervical
cancer
11. I would need
the HPV
vaccine if I
regularly used
a condom
when
engaging in
sexual activity
12. I would need
the HPV
vaccine if I
engaged in

54
89%
(n = 398)

90.3%
(n = 28)

88.9%
(n = 370)

-.01

1 ***

88.8%
(n = 334)

91.4%
(n = 64)

.031

.66*

90.2%
(n = 403)

87.1%
(n = 27)

90.4%
(n = 376)

.03

.53**

90.2%
(n = 339)

91.4%
(n = 64)

.016

.91*

84.8%
(n = 379)

71%
(n = 22)

85.8%
(n = 357)

.11

.05*

84.8%
(n = 319)

85.7%
(n = 60)

.009

.85

78.7%
(n = 352)

74.2%
(n = 23)

79.1%
(n = 329)

.03

.68*

79%
(n = 297)

78.6%
(n = 55)

-.004

.94

80.3%
(n = 359)

67.7%
(n = 21)

81.3%
(n = 338)

.13

.07

81.6%
(n = 305)

74.3%
(n = 52)

-.068

.15
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sexual activity
with a same
sex partner
13. I would need
the HPV
vaccine if I
had a steady
long-term
partner
14. I would need
the HPV
vaccine if I
smoked
15. I would need
the HPV
vaccine if I
engaged in
sexual activity
with a partner
of the
opposite sex
16. I would need
the HPV
vaccine if I
engage in
unprotected
sexual activity
17. The HPV
vaccine has
significant
side effects
18. The HPV
vaccine was
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71.4%
(n = 319)

58.1%
(n = 18)

72.4%
(n = 301)

.08

.09

71.8%
(n = 270)

70%
(n = 49)

-.015

.77

48.8%
(n = 218)

54.8%
(n = 17)

48.3%
(n = 201)

-.03

.48

49.2%
(n = 185)

47.1%
(n = 33)

-.015

.75

87%
(n = 389)

83.9%
(n = 26)

92.5%
(n = 363)

.08

.17*

87.5%
(n = 329)

85.7%
(n = 60)

-.019

.68

91.9%
(n = 411)

83.9%
(n = 26)

92.8%
(n = 385)

.084

.085**

91.8%
(n = 345)

94.3%
(n = 66)

.034

.63**

27.7%
(n = 124)

22.6%
(n = 7)

28.1%
(n = 117)

.031

.65*

29%
(n = 109)

21.4%
(n = 15)

-.061

.2

68.9%
(n = 308)

54.8%
(n = 17)

70%
(n = 291)

.083

.08

68.4%
(n = 257)

72.9%
(n = 51)

.035

.45
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thoroughly
tested
19. The HPV
21.9%
vaccine is
(n = 98)
likely to cause
health
problems
20. I could get
11%
HPV from the
(n = 49)
vaccine
21. I am
14.8%
concerned my
(n = 66)
family would
find out if I
got the HPV
vaccine
22. I am
12.5%
concerned my
(n = 56)
friends would
find out if I
got the HPV
vaccine
23. The HPV
82.6%
vaccine is an
(n = 369)
effective way
to prevent
HPV infection
24. Overall, the
84.8%
HPV vaccine
(n = 379)
is safe
* Yates continuity correction
**Fisher’s Exact Test
 (Phi) = effect size
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25.8%
(n = 8)

21.6%
(n = 90)

-.026

.75*

23.9%
(n = 89)

12.9%
(n = 9)

-.095 .064*

3.2%
(n = 1)

11.5%
(n = 48)

.068

.23**

11.4%
(n = 453

8.6%
(n = 6)

-.033

.62*

19.4%
(n = 6)

14.4%
(n = 60)

-.04

.63*

15.7%
(n = 59)

8.6%
(n = 6)

-.073

.17*

16.1%
(n = 5)

12.3%
(n = 51)

-.04

.73*

13.6%
(n = 51)

7.1%
(n = 5)

-.07

.19*

77.4%
(n = 24)

82.9%
(n = 345)

.04

.59*

82.2%
(n = 309)

85.7%
(n = 60)

.034

.47

77.4%
(n = 24)

85.3%
(n = 355)

.06

.36

84%
(n = 316)

90%
(n = 63)

.061

.27
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Table 8: Chi-square Analysis for Independent Groups – Uptake
Belief Vaccine Causes Problems
Uptake
(None)

Yes
78.4% (n = 69)

No
97.4% (n = 300)
Offered (in general)


.58

p
<.001

Yes
2.3%% (n = 7)

No
49.6% (n = 69)


-.58

p
<.001

Gender

Uptake
(>1 dose)

Male
38.7% (n = 12)

Female
71.2% (n = 296)
Student Classification


-.18

p
<.001

Undergraduate
69.9% (n = 263)

Graduate
64.3% (n = 45)
Preventative Healthcare


-.045

p
.35

Yes
71.6% (n = 285)

No
46.9% (n = 23)
HPV Education


.17

p
<.001

Yes
73.7% (n = 263)

No
50% (n = 45)
Provider Offered


-.21

p
<.001

Yes
88.4% (n = 259)

No
31.8% (n = 49)
Belief Virus Causes Problems


.58

p
<.001

Yes

No



p
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26.9% (n = 83)

73.1% (n =225)

.16

.001


-.32

p
<.001

Belief Vaccine Causes Problems
Yes
21.6% (n = 30)

No
78.4% (n = 109)
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Table 9: PAPM Staging
Stage

Stages 1 and 2:
I never seriously thought about
getting the HPV vaccination.
Stage 3:
I have seriously thought about
getting the HPV vaccination but
have not thought about it in past 6
months.
Stage 4:
I have seriously thought about
getting the HPV vaccination but
decided against it.
Stage 5:
I am seriously thinking about
getting the HPV vaccination
sometime within the next 6
months.
Stage 5, transitioning to Stage 6:
I plan to get the HPV vaccination
within the next month.

All

Gender

Student

Classification

60.4% (n = 84)

Male
78.9% (n = 15)

Female
57.5% (n = 69)

Undergrad
61.9% (n = 70)

Graduate
52% (n = 13)

10.1% (n =14)

10.5% (n = 2)

10% (n = 12)

10.6% (n = 12)

8% (n = 2)

17.3% (n = 24)

5.3% (n = 1)

19.2% (n = 23)

14.2% (n = 16)

32% (n = 8)

10.8% (n = 15)

5.3% (n = 1)

11.7% (n = 14)

11.5% (n = 13)

8% (n = 2)

1.4% (n = 2)

0% (n = 0)

1.7% (n = 2)

1.8% (n = 2)

0% (n = 0)
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Table 10: Chi-square Analysis for Preventative Care and Never Getting the Vaccine
Have Never Thought about
Getting the HPV Vaccine
Preventative Healthcare
22.6% (n = 19)
No Preventative Healthcare
77.4% (n = 65)
2
Pearson Chi-square:  (1, N = 139) = 2.14,  = .12, p = .21 (Yates)

Have Thought about Getting
HPV Vaccine
12.7% (n = 7)
87.3% (n = 48)

Running head: HPV VACCINATION
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Table 11: Factors Associated with Vaccination
95% CI for
Odds Ratio
 (SE)
Provider
Offered
Family Wanted
Friends Wanted

2.357
(.412)
3.678
(.623)
-.262
(1.240)
-2.528
(.688)

Wald
Statistic
32.807

df

p

Lower
4.715

Odds
Ratio
10.564

1

.000

34.907

1

.045

1

Upper
23.669

.000

11.680

39.566

134.032

.832

.068

.769

8.736

Belief the
.688
1
.000
.021
.080
.307
Vaccine Causes
Problems
Belief the Virus
.873 (.440)
.440
1
.047
1.011
2.394
5.668
Causes
Problems
No One Offered
-2.043
.589
1
.001
.041
.130
.411
Constant
-.997
.400
1
.013
.369
CI = Confidence interval; Hosmer & Lemenshow 2 (6, N = 447) = 8.358, p = .21; Nagelkerke
R2 = .501; Cox & Snell R2 = .71.
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Appendix A: Letter of Invitation

October 1, 2019
Dear Belmont Nursing Students,
We are writing to ask for your help by participating in a short, online survey on human papilloma
virus (HPV) and HPV vaccination. The purpose of this project is to assess knowledge and
concerns of HPV and HPV Vaccination in nursing students. This survey does not ask questions
about your personal or sexual history.
Undergraduate and graduate participants will have the opportunity to win one of four $25
Amazon gift cards through a randomized drawing. All nursing students, 18 years and older, are
eligible to participate. The survey should take approximately 5 minutes to complete. Your
participation is voluntary, and your responses will be kept confidential and anonymous. If you
choose to participate you may choose to discontinue participation at any time and you may
choose any of the survey questions that you do not wish to answer. Your completion of the
survey and returning it to the investigators indicates your consent to participate in this study. If
you have any questions, please contact Joanna Plumb via the contact information below.
You can access the online, mobile -friendly survey through these options:
Survey on HPV and HPV Vaccination
Or copy and paste the URL code into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_domFUFv6m57F2UR
Or scan the QR code

Thank you for your participation in this survey,
Joanna Plumb
DNP Candidate
Belmont School of Nursing
e: joannamarie.plumb@belmont.edu
cell: (615) 618-0412

Dr. Martha Buckner
Associate Dean of Nursing
Belmont School of Nursing

Dr. Jeannie Giese
Faculty-Sponsor, Associate Professor
Belmont School of Nursing, Inman 203-D
e: jeannie.giese@belmont.edu
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Appendix B: QR Code

HPV and HPV Vaccine Survey

You may access the survey through the link sent to your
school email
OR scan this QR Code:

Thank you for your participation!
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Appendix C: HPV Vaccination Survey
Demographics

Q1 Are you 18 or older?

o
o

Yes
No

Q2 How old are you? Please enter a 2-digit whole number.
Q3 Are you an undergraduate or graduate student?

o
o

Undergraduate
Graduate

Q4 Have you had education on HPV or HPV vaccination?

o
o

Yes
No

Q5 What is your ethnicity?

o
o
o
o
o
o

Caucasian
African American
Hispanic
Middle Eastern
Asian
Other

HPV VACCINATION
Q6 Are you receiving routine, preventative health care?

o
o

Yes
No
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Knowledge

Q7 Please answer the following true or false questions regarding HPV and the HPV vaccine.
True
Genital
wartsPlease
are caused
Start
of Block:
Rateby
HPV
HPV can cause cervical
End of Block:cancer
True or False
Abnormal pap tests may
indicate
thatPlease
a woman
has
Start of Block:
Rate
HPV
End of Block: True or False
HPV can cause penile cancer
Start
of Block:
Please by
Rate
HPV
is transmitted
skinto-skin contact
HPV infects both men and
Start of Block:
Rate
womenPlease
equally
HPV is sexually transmitted
I can transmit HPV even if I
don't have symptoms
Most persons with HPV have
no visible signs or symptoms
HPV can lay dormant in the
body for years without
symptoms
There is a vaccine available to
prevent HPV infection
There is no cure for HPV
Most adults are infected with
HPV
HPV infection among men is
rare
HPV can cause oral and throat
cancer
HPV can cause anal cancer
There is routine HPV
screening for men
There are many types of HPV
The HPV vaccine covers
certain HPV strains

o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o

False

o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
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Concerns and Opinions about HPV

Q8 Please rate your concerns and opinions regarding HPV.
Strongly
agree

Somewhat
Agree

Neutral

Somewhat
disagree

Strongly
disagree

I am at high risk for
getting HPV

o

o

o

o

o

I am likely to contract
the HPV virus in my
lifetime

o

o

o

o

o

HPV would be a serious
threat to my sex life

o
o

o
o

o
o

o
o

o
o

HPV would make it
difficult to find a longterm partner

o

o

o

o

o

I would tell my sexual
partner if I had HPV

o

o

o

o

o

If I had HPV I would be
at risk for transmitting
it to others

o

o

o

o

o

I would need the HPV
vaccine if I had a high
number of sexual
partners

o

o

o

o

o

I would need the HPV
vaccine if I had
multiple sexual partners

o

o

o

o

o

I would need the HPV
vaccine if I had a family
history of cervical
cancer

o

o

o

o

o

I would need the HPV
vaccine if I regularly
used a condom when
engaging in sexual
activity

o

o

o

o

o

HPV would be a severe
threat to my health
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Strongly
agree

Somewhat
Agree

I would need the
HPV vaccine if I
engaged in sexual
activity with a same
sex partner

o

o

o

o

o

I would need the
HPV vaccine if I had
a steady long-term
partner

o

o

o

o

o

I would need the
HPV vaccine if I
smoked

o

o

o

o

o

I would need the
HPV vaccine if I
engaged in sexual
activity with a partner
of the opposite sex

o

o

o

o

o

I would need the
HPV vaccine if I
engage in unprotected
sexual activity

o

o

o

o

o

The HPV vaccine has
significant side
effects

o

o

o

o

o

The HPV vaccine
was thoroughly tested

o

o

o

o

o

The HPV vaccine is
likely to cause health
problems

o

o

o

o

o

I could get HPV from
the vaccine

o

o

o

o

o

I am concerned my
family would find out
if I got the HPV
vaccine

o

o

o

o

o

Neutral

Somewhat
disagree

Strongly
disagree
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Strongly
agree

Somewhat
Agree

Neutral

Somewhat
disagree

Strongly
disagree

I am concerned my
friends would find
out if I got the HPV
vaccine

o

o

o

o

o

The HPV vaccine is
an effective way to
prevent HPV
infection

o

o

o

o

o

Overall, the HPV
vaccine is safe

o

o

o

o

o

Q9 How many HPV vaccine doses have you received?

o
o
o

0
1
2 or more

Q10 Have you thought about getting the HPV vaccine?

o
o
o
o
o

I never seriously thought about getting the HPV vaccination.
I have seriously thought about getting the HPV vaccination but have not thought about it
in past 6 months.
I have seriously thought about getting the HPV vaccination but decided against it.
I am seriously thinking about getting the HPV vaccination sometime within the next 6
months
I plan to get the HPV vaccination within the next month.
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Q11 Which factors influenced you to receive the vaccine or not to receive the vaccine?

▢
▢
▢
▢
▢
▢

Provider Offered Vaccine
Family wants you to get vaccine
Friends wants you to get vaccine
Belief that the vaccine causes health problems
Belief that the virus causes health problems
No one has offered the vaccine

Q12 What is your gender?
We recognize there are multiple genders, but due the nature of this study, we ask for your
biological gender (sex you are born with).

o
o
o

Male
Female
Other ________________________________________________

70

